Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Psilocybin for Demoralization
NCT05227742Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2023
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Demoralization at 8 weeks, Mystical Experience at 7 weeks and 4 more. Planned start Aug 2023; status: withdrawn.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT05227742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227742.